To determine if the progression-free survival of patients with High Grade Astrocytoma who are treated with TVB-2640 in combination with bevacizumab is superior to treatment with bevacizumab alone.
To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade Astrocytoma.
To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier where it might have the opportunity to affect tumor tissue metabolism.
To evaluate the Objective Response Rate (ORR) of poziotinib in patients with HER2-positive metastatic breast cancer (MBC)
To assess the safety and tolerability of poziotinib in patients with HER2-positive MBC
To evaluate other efficacy variables of poziotinib in patients with HER2-positive MBC,
including the following:
Progression-Free Survival (PFS)
Disease Control Rate (DCR)
Overall Survival (OS)
Time to Progression (TTP)
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
¿ To evaluate the antitumor activity of niraparib in patients with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer as assessed by overall response rate (ORR)
¿ To evaluate the durability of the antitumor activity of niraparib
¿ To evaluate antitumor activity of niraparib in homologous recombination deficiency (HRD)-positive patients and in patients with germline breast cancer gene mutation (gBRCAmut)
¿ To evaluate the following additional measures of clinical benefit of niraparib:
¿ Disease control rate (DCR)
¿ Progression-free survival (PFS)
¿ Overall survival (OS)
¿ To evaluate the safety and tolerability of niraparib
¿ To evaluate QTc in a subset of niraparib-treated ovarian cancer patients
¿ To assess population pharmacokinetics (PK) and estimate PK parameters for niraparib and its major metabolite
¿ To explore potential biomarkers of poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity and tolerability